Every 8-K that Inspire Veterinary Partners, Inc. (IVP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVP filings page.
Inspire Veterinary Partners, Inc. reported that director Erinn Thomas-Mackey resigned from its board of directors, effective immediately on February 26, 2026. The company stated that her resignation was not related to any disagreement regarding its operations, policies, or practices.
The update focuses solely on this board change and confirms that she did not raise disputes about how the business is being run.
Inspire Veterinary Partners, Inc. announced that a Nasdaq Hearings Panel has denied its request to continue listing on Nasdaq after the company failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, its common stock was suspended from trading on The Nasdaq Capital Market at the open on January 21, 2026 and will be delisted, with Nasdaq expected to file a Form 25 to remove the securities from listing and registration. The company has received approval for its common stock to trade on the OTCQB Venture Market under the symbol “IVPR,” where trading also began on January 21, 2026. Inspire Veterinary states that it intends to continue filing periodic reports with the SEC.
Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC on January 14, 2026. The company agreed to cancel $25,000 of outstanding principal under a June 10, 2025 promissory note in exchange for 2,500,000 shares of its Class A common stock. The share amount was set by dividing the cancelled debt by $0.01 per share, effectively converting part of the debt into equity rather than paying cash. The exchange relied on the registration exemption in Section 3(a)(9) of the Securities Act, while the related offer was treated as a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D.
Inspire Veterinary Partners, Inc. reported that it has amended its Articles of Incorporation to significantly increase its authorized Class A common stock. The amendment, effective upon filing on January 9, 2026, raises the authorized Class A common shares from 100,000,000 to 700,000,000, while leaving the authorized Class B common and preferred stock unchanged. The change was approved by the board of directors and stockholders holding the requisite voting power and is documented in a Certificate of Amendment filed with the Nevada Secretary of State.
Inspire Veterinary Partners, Inc. entered into a securities purchase agreement with Manetto Hill Fund Series I LLC under which the company may issue up to $1,626,000 principal amount of secured convertible promissory notes. On January 6, it issued an initial Note with $975,000 principal for a $750,000 purchase price, bearing 10% annual interest and maturing on December 31, 2026. The Note is convertible at Manetto’s option at the lesser of $0.06 per share or 80% of the lowest traded share price over a 15‑day look-back, with a floor of $0.01 per share, and includes additional downward adjustments in specified circumstances. The company will also issue up to 2,500,000 commitment shares and has granted Manetto a first‑priority security interest in certain veterinary clinics. Inspire agreed to file and maintain a registration statement for the resale of the conversion and commitment shares, and plans to use proceeds for general working capital and acquisitions. The company also reported the immediate resignation of director Timothy Watters, stating it did not result from any disagreement with the company.
Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC on December 18, 2025. Under this deal, the company cancelled $150,000 of outstanding principal on a June 10, 2025 promissory note in exchange for 3,000,000 shares of Class A common stock, based on a price of $0.05 per share. This transaction reduces debt while increasing the company’s share count.
The exchange and related offer of securities were completed as an unregistered private placement, relying on exemptions from registration under Section 3(a)(9), Section 4(a)(2), and Rule 506(b) of Regulation D. The full terms are set out in the Cancellation and Exchange Agreement filed as an exhibit.
Inspire Veterinary Partners, Inc. entered into a new Consulting Agreement with 622 Capital LLC on December 12, 2025. Under this agreement, the consultant will provide business development services focused on business financing opportunities.
As consideration for these services, Inspire Veterinary Partners agreed to issue an aggregate of 9,450,000 shares of its Class A common stock. Of this total, 3,300,000 shares were issued upon execution of the agreement, and an additional 6,150,000 shares are issuable within five business days after execution. These shares are being issued under the company’s 2022 Equity Incentive Plan and are registered on a Form S-8. The agreement also includes customary representations, covenants, indemnification, and confidentiality provisions and remains in effect until terminated according to its terms.
Inspire Veterinary Partners, Inc. reported that Nasdaq has notified the company its common stock no longer meets the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days with a low closing bid price. Nasdaq stated the company’s securities would be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE would be filed to remove the securities from listing and registration, unless the company appealed. The company requested a hearing before Nasdaq’s Hearings Panel by November 20, 2025, which stays any suspension or delisting action during the process. On November 21, 2025, the company was informed that the hearing is scheduled for January 13, 2026, and it cautions there can be no assurance it will retain its Nasdaq listing or regain compliance.
Inspire Veterinary Partners, Inc. (IVP) has received a notice from Nasdaq stating that its common stock no longer meets the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notice also explains that the company is not eligible for an automatic compliance period because it has completed reverse stock splits over the past one and two years with a cumulative ratio of 250 shares or more to one under Listing Rule 5810(c)(3)(A)(iv). Nasdaq has stated that IVP’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, with a Form 25-NSE filed to remove the securities from listing and registration, unless the company appeals by November 20, 2025. IVP plans to request a hearing, which will temporarily halt the suspension or delisting process, but there is no assurance it will retain its Nasdaq listing.
Inspire Veterinary Partners (IVP) entered a financing agreement, issuing two Senior Convertible Promissory Notes on November 5, 2025 to Keystone Capital Partners, LLC and Seven Knots, LLC. Each note has $178,571.43 principal with a 30% original issue discount, for a $125,000 purchase price per note, bears 10% annual interest paid monthly, and matures on August 5, 2026, unless earlier converted or repaid.
The notes are convertible at the holder’s option at a price equal to 90% of the lowest sale price over the 20 trading days before conversion, with an adjustment if the Company later issues at a lower price. A 4.99% beneficial ownership cap applies, adjustable up to 9.99% with notice. The Company must prepay 25% of gross proceeds from its existing equity line with Seven Knots at a 120% premium, and a $1,000,000 Qualified Financing triggers full repayment at a 120% premium. Upon default, amounts may be accelerated at 120% and interest increases to up to 24% per annum. Proceeds are for general working capital.
Inspire Veterinary Partners (IVP) changed auditors. On October 16, 2025, the company dismissed Kreit & Chiu CPA LLP and appointed M&K CPAS, PLLC as its independent registered public accounting firm to audit the financial statements for the year ended December 31, 2025. The Audit Committee approved the change.
The company reported no disagreements with Kreit & Chiu on accounting principles, disclosure, or audit procedures. Kreit & Chiu previously identified material weaknesses in internal control over financial reporting, and its audit reports for 2024 and 2023 included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern. A letter from Kreit & Chiu dated October 21, 2025 is filed as Exhibit 16.1.
Inspire Veterinary Partners, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), known as the stockholders’ equity requirement. Nasdaq notified the company on August 26, 2025 that, based on a filing made with the SEC on August 20, 2025, the company now meets the required level of stockholders’ equity for continued listing on the Nasdaq Capital Market. The company later issued a press release on September 2, 2025 to publicly announce that it is once again in compliance with this Nasdaq listing standard.
Inspire Veterinary Partners, Inc. reported that Nasdaq previously notified the company on April 10, 2025 that its stockholders’ equity of $1,562,005 as of December 31, 2024 did not meet the Nasdaq Capital Market minimum under Listing Rule 5550(b)(1). The company submitted a compliance plan within the required 45-day window.
The company then entered into a Securities Purchase Agreement on July 28, 2025 for a private placement of up to 7,590 shares of Series B convertible preferred stock and accompanying warrants, with an aggregate offering amount of up to $10 million, to be sold in one or more closings. On July 29, 2025, it completed the first closing, issuing 6,340 shares of Series B Preferred Stock and 6,340,000 warrants for aggregate proceeds of approximately $5 million, received in cash and in securities in lieu of cash.
As of this report, the company believes that, because of the first closing of the private placement, it has regained compliance with Nasdaq’s stockholders’ equity requirement. Nasdaq will continue to monitor compliance, and the company may be subject to delisting if a future periodic report does not show that it remains in compliance.
Inspire Veterinary Partners (Nasdaq: IVP) filed an 8-K disclosing two capital-raising arrangements that could supply up to $60 million of new funding but introduce meaningful dilution.
On 28-29 Jul 2025 the company signed a Securities Purchase Agreement for a private placement of up to 7,590 Series B convertible preferred shares (stated value $1,000) plus equal-number warrants. At the first closing investors bought 6,340 preferred shares and 6,340,000 five-year warrants for $5 million. The preferred converts at $1.00 per share (floor $0.1876) and the warrants initially exercise at $1.00, both subject to reset on lower-priced issuances. The stock ranks senior to all other equity, has no voting rights, and carries standard anti-dilution, redemption (125% premium) and change-of-control protections. The company must reserve 250 % of the shares needed for conversion and file a resale registration statement.
Separately, IVP entered a $50 million committed equity line with a single accredited investor. IVP may, at its option, sell up to $5 million of common stock per notice when the market price is ≥$0.75, subject to a 4.99 % ownership cap. Proceeds are earmarked for working capital. Either party can terminate under customary default, delisting or bankruptcy triggers.
- Aggregate potential raise: $60 million
- Immediate cash received: ~$5 million
- Maximum dilution: variable; conversion and warrant floors set at ~$0.19